Chloroquine resistance was present in 58 (53%) of 113 assessable study
S
BackgroundTreatment failure of chloroquine for P
Plasmodium vivax is the most prevalent malaria species in the Americas
Some resistant strains to chloroquine (CQ) occur in a few places in Asia and the Indo-Pacific Region (1–4)
Data on chloroquine (CQ)-resistant Plasmodium vivax in Latin America is limited, even with the current research efforts to sustain an efficient malaria control program in all these countries where P
3 million annually and are often life threatening 1
We performed a prospective study with 28-day follow-up of clinical responses to chloroquine in 2 P
Plasmodium vivax resistance to chloroquine (CQ) is currently reported in almost all countries where P
Both species are likely exposed to drug pressure from a number of anti-malarials including chloroquine, sulphadoxine-pyrimethamine (SP), and
3201/eid1307
Purpose of review: Unlike Plasmodium falciparum, Plasmodium vivax rarely causes severe disease in healthy travellers or in temperate endemic regions and has been regarded as readily treatable with chloroquine
To the Editor: Plasmodium vivax is the protozoan that causes the second most common form of malaria
China continues to be plagued by imported malaria cases, and preventing re-transmission of imported malaria is critical
vivax (CRPv) has started to challenge the efficacy of the drug
vivax and 38
In this study, we investigated the in vitro chloroquine susceptibility profile and molecular polymorphisms of P
2016 Nov;4(11):e790
2 There have been sporadic reports of chloroquine resistance in the country
5 mg per kilogram through day 168 Plasmodium falciparum chloroquine resistance is a major cause of worldwide increases in malaria mortality and morbidity